MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Kodu・Aktsiate loetelu・Editas Medicine Inc

Editas Medicine Inc

Suletud

SektorTervishoid

2.11 4.46

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.01

Max

2.11

Põhinäitajad
By Trading Economics
Sissetulek	28M -25M
Müük	4M 7.5M
Kasumimarginaal	-332.984
Töötajad	246
EBITDA	27M -22M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+99.01% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-77M 198M
Eelmine avamishind	-2.35
Eelmine sulgemishind	2.11

Uudiste sentiment

By Acuity

50%

177 / 360 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.33 / 1.54 Toetus ja vastupanu

Editas Medicine Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. jaan 2026, 23:49 UTC

Suurimad hinnamuutused turgudel

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21. jaan 2026, 21:12 UTC

Suurimad hinnamuutused turgudel

Automaker Stocks Rise After Trump Calls Off European Tariffs

21. jaan 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21. jaan 2026, 20:29 UTC

Suurimad hinnamuutused turgudel

Chip Makers Gain After Trump Calls Off European Tariffs

21. jaan 2026, 20:04 UTC

Suurimad hinnamuutused turgudel

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21. jaan 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21. jaan 2026, 22:39 UTC

Tulu

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. jaan 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21. jaan 2026, 21:19 UTC

Tulu

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21. jaan 2026, 20:45 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19B

21. jaan 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21. jaan 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21. jaan 2026, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21. jaan 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. jaan 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21. jaan 2026, 20:26 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21. jaan 2026, 20:23 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21. jaan 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21. jaan 2026, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Group Agrees to Buy Allfunds

21. jaan 2026, 20:08 UTC

Tulu

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21. jaan 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21. jaan 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21. jaan 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21. jaan 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21. jaan 2026, 19:24 UTC

Tulu

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21. jaan 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21. jaan 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Editas Medicine Inc Prognoos

Hinnasiht

By TipRanks

99.01% tõus

12 kuu keskmine prognoos

Keskmine 4.02 USD 99.01%

Kõrge 5 USD

Madal 3 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Editas Medicine Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Editas Medicine Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.33 / 1.54Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

177 / 360 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.